A Supratherapeutic Dose of the Janus Kinase Inhibitor Tasocitinib (CP-690,550) Does Not Prolong QTc Interval in Healthy Participants

Deferasirox does not induce QT/QTc-prolongation in healthy subjects

(2011) R. Sechaud et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Comparison of Manual and Automated Measurements of the QT Interval in Healthy Volunteers: An Analysis of Five Thorough QT Studies

(2009) C Fosser et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Effects of Standard and Supratherapeutic Doses of Nelfinavir on Cardiac Repolarization: A Thorough QT Study

(2009) Bharat Damle et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics and Pharmacodynamic, Pharmacokinetic, Pharmacodynamic, and Electrocardiographic Effects of Dapoxetine and Moxifloxacin Compared With Placebo in Healthy Adult Male Subjects

(2009) Nishit B. Modi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A Thorough QTc Study to Assess the Effect of Sitagliptin, a DPP4 Inhibitor, on Ventricular Repolarization in Healthy Subjects

(2009) Daniel M. Bloomfield et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis

(2009) Mary G. Boy et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

The Effect of Moxifloxacin on QTc and Implications for the Design of Thorough QT Studies

(2008) DM Bloomfield et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Raltegravir Thorough QT/QTc Study: A Single Supratherapeutic Dose of Raltegravir Does Not Prolong the QTcF Interval

(2008) M. Iwamoto et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY